Glaucoma is an eye condition characterised by intraocular pressure (IOP) in one or both eyes. In order to prevent the progression to visual field loss, IOP should be reduced. Several posters presented at the 8th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Arlington, US; May 2003] evaluated the cost effectiveness of various therapies for treating glaucoma. All of the presentations were funded by Allergan, Inc., US.1,2,3,4